SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-22-017938
Filing Date
2022-08-31
Accepted
2022-08-31 07:00:42
Documents
10
Period of Report
2022-09-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A acasti_def14a_2022.htm DEF 14A 1385961
2 GRAPHIC img54545166_0.jpg GRAPHIC 71725
3 GRAPHIC img54545166_1.jpg GRAPHIC 106699
4 GRAPHIC img54545166_2.jpg GRAPHIC 149568
5 GRAPHIC img54545166_3.jpg GRAPHIC 142425
6 GRAPHIC img54545166_4.jpg GRAPHIC 23416
7 GRAPHIC img54545166_5.jpg GRAPHIC 20867
8 GRAPHIC img54545166_6.jpg GRAPHIC 10444
9 GRAPHIC img54545166_7.jpg GRAPHIC 163391
10 GRAPHIC img54545166_8.jpg GRAPHIC 89748
  Complete submission text file 0000950170-22-017938.txt   2460010
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: DEF 14A | Act: 34 | File No.: 001-35776 | Film No.: 221216248
SIC: 2834 Pharmaceutical Preparations